Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor
Oculis Holding (OCS) has agreed to acquire all of Accure Therapeutics' worldwide development and com
Keep reading this article with Yahoo Finance Plus Silver
Silver
- Premium news Full access to Financial Times and MT Newswires articles
- Stock picks Expert picks from Motley Fool, Zacks, and Moby
- Research reports Expert analysis from Morningstar and Argus
